Holen Sie sich die Stockscreener-App
0.2822
1.29%
0.0029
Renovaro Inc Aktie (RENB) Neueste Nachrichten
Renovaro Inc (RENB Stock: A Sea of Opportunity - investchronicle.com
Ratios Uncovered: Breaking Down Renovaro Inc (RENB)’s Trailing Twelve Months Metrics - DWinneX
Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics - MSN
Smart Healthcare Is Taking Over. Here's Where the Money's Headed - Finansavisen
Renovaro Inc. (NASDAQ:RENB) Shares Bought by Nuveen Asset Management LLC - Defense World
POAIRenovaro Issues Shareholder Letter and Provides Corporate Update - Revista ADVFN
Renovaro Biosciences Subsidiary CEO Resigns Abruptly - TipRanks
Deutsche Bank AG Takes $107,000 Position in Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro subsidiary secures patent for drug discovery AI By Investing.com - Investing.com South Africa
RENB stock touches 52-week low at $0.27 amid market challenges - Investing.com Australia
Renovaro's BioSymetrics Unit Gets Notice of Allowance for New Patent - MarketScreener
Renovaro (RENB) Secures Patent to Enhance AI in Drug Discovery | - GuruFocus
Renovaro Inc. Skyrockets on AI Patent Win: What’s Fueling the Frenzy? - RagingBull
Renovaro (RENB) Secures Patent to Enhance AI in Drug Discovery | RENB Stock News - GuruFocus
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Di - GuruFocus
Renovaro subsidiary secures patent for drug discovery AI - Investing.com
Renovaro secures U.S. patent for AI-driven drug discovery, diagnostics platform - TipRanks
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform | RENB Stock News - GuruFocus
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform - GlobeNewswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 41,296 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro Inc. (NASDAQ:RENB) Shares Acquired by Northern Trust Corp - Defense World
Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World
What Analysts Think About Renovaro Inc (NASDAQ: RENB)’s Potential Raise - Stocksregister
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Court Denies Renovaro Motion for an Expedited Trial in July | P - GuruFocus
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Major Moves And Shakes In Health Care Sector - Finimize
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge - Nasdaq
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Court Fast-Tracks Renovaro's Lawsuit to Force Merger After Predictive Oncology's $545K Securities Breach - Stock Titan
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro announces expedited trial on suit to enforce Predictive Oncology merger - TipRanks
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):